Moderna Inc. ($MRNA) Stock Forecast: Up 5.7% Today

What is Moderna Inc.?

Moderna, Inc. ($MRNA) is a biotechnology company acclaimed for its mRNA technology used in developing vaccines and therapeutics. The stock demonstrated a robust upturn today.

Why is Moderna Inc. going up?

MRNA stock is up 5.7% on Jan 29, 2026 18:27

• Moderna's stock soared as investors exhibited confidence in the company's innovative mRNA technology and its promising prospects for growth.
• The decision by Federated Hermes Inc. and director Noubar Afeyan to reduce their stake may have sparked some initial market uncertainty, but the prevailing sentiment leaned towards positivity.
• The stock's remarkable performance could also be linked to its inclusion in the top healthcare stocks list, showcasing its resilience and growth potential in the sector.
• The increased market interest in healthcare stocks, evident from the leading ETFs and the focus on NLRP3 inhibitors by other entities, likely contributed to the further elevation of Moderna's stock price.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

3 ETFs Catapulting Beyond the S&P to Start the Year

This article highlights three ETFs that have significantly outperformed the S&P 500 early in the year 2026. These include the REX Drone ETF (DRNZ) focusing on pure-play drone technology, the Sprott Nickel Miners ETF (NIKL) which is a pure-play nickel miner fund, and the YieldMax MRNA Option Income Strategy ETF (MRNY) using a covered call strategy on Moderna. Each ETF offers unique exposure to high-growth sectors or specialized strategies, demonstrating strong returns year-to-date.

https://finviz.com/news/291476/3-etfs-catapulting-beyond-the-sp-to-start-the-year

Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential

Both Eli Lilly and BioAge Labs are actively developing NLRP3 inhibitors, recognizing their potential as a "pipeline in a pill" to treat a wide range of inflammation-driven diseases, including cardiovascular, neurodegenerative, and metabolic disorders. Eli Lilly recently acquired Ventyx Biosciences for $1.2 billion for its NLRP3 inhibitor pipeline, while BioAge's oral inhibitor, BGE-102, showed promising results in a Phase 1 study for cardiovascular risk factors and plans to expand into ophthalmology. The early-stage development of these drugs aims to offer more convenient oral treatments to address the significant role of inflammation in chronic illnesses.

https://www.pharmavoice.com/news/eli-lilly-bioage-nlrp3-inhibitors-cardio-pharma-drug/810788/

Teradyne, Inc. (NASDAQ:TER) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Teradyne (NASDAQ: TER) shares have surged 27% in the last month, contributing to a 105% increase over the past year. Despite this, its high price-to-sales (P/S) ratio of 13.7x suggests that the stock might be overvalued compared to its industry peers, especially given its revenue growth rate is slower than the industry average. Analysts predict weaker revenue growth for Teradyne, indicating that its current elevated P/S ratio might not be sustainable if investor sentiment aligns with these forecasts.

https://simplywall.st/stocks/us/semiconductors/nasdaq-ter/teradyne/news/teradyne-inc-nasdaqter-stock-rockets-27-as-investors-are-les

Moderna, Inc. $MRNA Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. has reduced its stake in Moderna (NASDAQ:MRNA) by 3.1%, selling 90,270 shares, while director Noubar Afeyan also sold a significant portion of his holdings. Despite beating EPS estimates, Moderna's revenue was down 45.4% year-over-year, leading to a cautious "Reduce" consensus rating from Wall Street analysts with an average price target of $28.77. Institutional investors still hold a substantial 75.33% of the stock.

https://www.marketbeat.com/instant-alerts/filing-moderna-inc-mrna-shares-sold-by-federated-hermes-inc-2026-01-29/

Top performing healthcare stocks in the past month (MRNA:NASDAQ)

This article identifies the top 10 best-performing healthcare stocks with market capitalizations of $10 billion or more based on their one-month price performance as January 2026 concludes. It notes that earnings season is accelerating, putting these stocks in focus. The list serves as a snapshot of strong performers in the healthcare sector for the given period.

https://seekingalpha.com/news/4543642-top-performing-healthcare-stocks-in-the-past-month

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 7.3% Today

Pepe ($PEPE) Crypto Forecast: Down 6.2% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 6.0% Today

Stellar ($XLM) Crypto Forecast: Down 7.0% Today

Dogecoin ($DOGE) Crypto Forecast: Down 7.4% Today

Bitcoin ($BTC) Crypto Forecast: Down 5.9% Today

Chiliz ($CHZ) Crypto Forecast: Down 12.2% Today

Worldcoin ($WLD) Crypto Forecast: Down 9.6% Today

XRP ($XRP) Crypto Forecast: Down 6.1% Today

Copper ($COPPER) Commodity Forecast: Down 6.1% Today

Moderna Inc. Price History

27.00.2026 - MRNA Stock was up 6.0%

• MRNA stock experienced a bullish movement today.
• The positive market sentiment towards MRNA could be attributed to recent advancements in personalized cancer vaccines by another company, potentially boosting confidence in the biotech sector.
• Additionally, positive developments in the biotech industry, such as progress with a therapy for bladder cancer by another company, may have created a ripple effect of optimism among investors, benefiting companies like MRNA.
• Overall, the growing interest and potential breakthroughs in the biotech field seem to have contributed to the bullish movement in MRNA stock today.

27.00.2026 - MRNA Stock was down 5.2%

• Moderna (MRNA) underwent a period of bearish movement, potentially influenced by positive developments and growth projections of major competitors in the oncology market, including Merck (MRK), Oncolytics Biotech Inc. (ONCY), and other industry participants.
• Merck's (MRK) anticipated rise in earnings and revenues, progress in its oncology pipeline, and revised growth forecasts might have redirected investor attention from Moderna, leading to a decline in its stock performance.
• Analysts' call for enhanced clarity on long-term growth prospects at Merck, despite its notable performance, may have prompted investor apprehensions regarding Moderna's competitiveness and future growth trajectory in biotechnology.
• References to AI stocks presenting superior upside potential compared to Merck could have shifted investor focus towards alternative investment options, thereby contributing to the downward trend in Moderna's stock value.

23.00.2026 - MRNA Stock was down 10.9%

• The stock's decline may have been driven by profit-taking by investors following a recent 4% rally linked to positive five-year follow-up data for their mRNA cancer vaccine in collaboration with Merck.
• Concerns about potential competition or market positioning for Moderna in the oncology sector could have arisen with the amendment of the license agreement between Terns Pharmaceuticals and Hansoh for TERN-701 rights.
• Investor focus and capital might have been redirected towards the banking sector, particularly awaiting Itaú Unibanco's Q4 results, contributing to Moderna's downward trend.
• Despite the promising long-term prospects in oncology, external factors and short-term market dynamics possibly influenced the bearish performance today.

23.00.2026 - MRNA Stock was down 9.4%

• Moderna's stock saw a strong bearish movement possibly due to the announcement of limiting investment in new late-stage vaccine trials, reflecting concerns over achieving returns amidst regulatory hurdles and opposition in the US market.
• The groundbreaking five-year follow-up data for their mRNA cancer vaccine, which demonstrated positive results in high-risk melanoma patients, might have been overshadowed by the decision to curb vaccine trial investments, leading to investor uncertainty.
• The amended license agreement with Hansoh for TERN-701 by Terns Pharmaceuticals could have also impacted Moderna's stock negatively, as it potentially shifts focus and resources away from certain therapeutic products.
• Overall, the market may be reacting to the shifting priorities and strategies within Moderna, as it navigates challenges in the regulatory landscape and transitions towards personalized cancer treatments, impacting investor sentiment and stock performance.

23.00.2026 - MRNA Stock was down 10.7%

• The stock's decline could be attributed to profit-taking or concerns about vaccine distribution challenges.
• Positive updates on Lucid Group, Materion Corp, and Terns Pharmaceuticals might have shifted investor focus away from Moderna.
• Other companies' positive news and Itaú Unibanco's upcoming investor meeting could have added to the downward pressure on Moderna's stock.
• Despite today's bearish movement, Moderna's long-term outlook remains optimistic due to its crucial role in the pandemic response and continuous vaccine innovations.

28.00.2026 - MRNA Stock was down 8.4%

• An analyst initiated coverage on Moderna with an "equal weight" rating and a $25.00 price target, indicating a significant downside potential from its current price. This negative sentiment from analysts likely contributed to the bearish movement.
• The weak fundamentals of Moderna, such as negative EPS and revenue declines, could have further fueled investor concerns and led to the sell-off.
• The lack of growth in revenue and poor financial outlook for biotech companies like BioNTech SE, may have cast a shadow on Moderna's prospects, impacting its stock performance.
• Overall, the combination of negative analyst ratings, weak financial fundamentals, and broader industry concerns about revenue growth in the biotech sector likely contributed to Moderna's bearish market movement today.

22.00.2026 - MRNA Stock was up 15.0%

• Moderna's bullish movement could be attributed to positive sentiment surrounding the company's COVID-19 vaccine sales and ongoing efforts in vaccine development.
• The market may be reacting favorably to the news of a global restructuring, potentially indicating investor confidence in companies adapting to optimize operations.
• Steady stock performance and positive outlook from an analyst firm could be contributing to a positive overall sentiment in the healthcare sector, benefiting companies like Moderna.
• A stock hitting a 52-week high and the positive analyst price target revisions could be boosting investor interest in the biotech sector, indirectly benefiting Moderna as well.

22.00.2026 - MRNA Stock was up 10.6%

• Moderna's bullish movement today could be attributed to positive sentiment surrounding the broader biotech sector and the company's ongoing efforts in vaccine development.
• The bullish market movement may also be influenced by the news of Bristol Myers partnering with Janux Therapeutics to develop novel tumor-activated therapeutics, highlighting the potential for innovative approaches in the healthcare industry.
• Additionally, the strong performance of other healthcare companies like Liquidia Technologies hitting an all-time high could have created a positive ripple effect in the sector, boosting investor confidence in Moderna's growth prospects.
• Overall, Moderna's bullish trend today seems to be driven by a combination of sector-wide optimism, positive developments in the healthcare industry, and potentially favorable market conditions for biotech companies.

22.00.2026 - MRNA Stock was up 12.0%

• The positive sentiment surrounding the efficacy and demand for Moderna's COVID-19 vaccine, as well as advancements in its pipeline for mRNA-based therapies, likely fueled the recent bullish movement.
• The collaboration between Janux Therapeutics and Bristol Myers Squibb could have played a role in boosting investor interest in biotech companies like Moderna.
• Abbott Laboratories' stock decline following revenue estimates miss may have indirectly benefited Moderna as investors potentially sought out companies with stronger growth potential.
• The selling of Merck & Co., Inc. shares by Bailard Inc. and other hedge funds may have shifted investments towards promising opportunities like Moderna, contributing to its bullish performance.

22.00.2026 - MRNA Stock was up 8.2%

• Moderna's stock surged by 4% following the groundbreaking five-year follow-up data for their mRNA cancer vaccine, showing a significant reduction in the risk of relapse or death in high-risk melanoma patients. This success not only boosted investor confidence in Moderna's technology but also solidified its position as a major player in oncology.
• The announcement of Moderna curbing investments in vaccine trials due to US backlash had a positive impact on the stock, with shares jumping by 10.16% in morning trading. This strategic shift towards personalized cancer treatments in response to regulatory hurdles demonstrates the company's adaptability and focus on long-term growth.
• The partnership between Bristol Myers Squibb and Janux Therapeutics in developing novel T cell engagers for solid tumors may have indirectly contributed to Moderna's bullish movement by highlighting the potential in oncology treatments, further fueling optimism in the biotech sector.
• Overall, Moderna's bullish market movement today can be attributed to its groundbreaking cancer vaccine data, strategic shift towards personalized treatments, and positive investor sentiment towards advancements in oncology therapies.

29.00.2026 - MRNA Stock was up 5.0%

• Moderna's bullish movement could be attributed to positive sentiment surrounding its ongoing developments and potential in the healthcare sector.
• The reduction in stake by Federated Hermes Inc. and director Noubar Afeyan might have initially raised concerns, but the market likely focused more on the broader positive outlook for the company.
• The strong performance of healthcare stocks in the past month, including Moderna, reflects investor confidence in the sector, further boosting MRNA's upward momentum.
• With the focus on NLRP3 inhibitors by other companies like Eli Lilly and BioAge Labs, the overall excitement and advancements in healthcare innovation could have positively influenced Moderna's stock performance.

29.00.2026 - MRNA Stock was up 5.7%

• Moderna's stock soared as investors exhibited confidence in the company's innovative mRNA technology and its promising prospects for growth.
• The decision by Federated Hermes Inc. and director Noubar Afeyan to reduce their stake may have sparked some initial market uncertainty, but the prevailing sentiment leaned towards positivity.
• The stock's remarkable performance could also be linked to its inclusion in the top healthcare stocks list, showcasing its resilience and growth potential in the sector.
• The increased market interest in healthcare stocks, evident from the leading ETFs and the focus on NLRP3 inhibitors by other entities, likely contributed to the further elevation of Moderna's stock price.